Form 4: Sangamo CFO Sells Shares for Tax Withholding

Sangamo Therapeutics' SVP and CFO, Prathyusha Duraibabu, disposed of 1,792 shares of common stock for mandatory tax withholding purposes.

Summary

• Prathyusha Duraibabu, SVP, Chief Financial Officer of Sangamo Therapeutics, Inc., reported a disposition of common stock.
• The transaction involved 1,792 shares of common stock.
• The shares were surrendered to the issuer for mandatory tax withholding related to the vesting of a restricted stock unit (RSU) grant.
• The disposition occurred on August 24, 2025, at a price of $0.5863 per share, based on the closing price on August 22, 2025.
• Following this transaction, Ms. Duraibabu beneficially owns 744,487 shares of common stock.
• This was not a discretionary trade but a required tax withholding transaction, as per the Issuer's Amended and Restated 2018 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary disposition for tax withholding purposes upon RSU vesting. It has a neutral impact on sentiment as it does not reflect a change in the insider's investment conviction or company outlook.

Positives

• The transaction was for mandatory tax withholding, not a discretionary sale, indicating no immediate negative sentiment from the insider.
• The CFO retains a significant beneficial ownership of 744,487 shares, aligning her interests with shareholders.

Negatives

• A small number of shares were disposed of, reducing the insider's direct holdings, albeit for tax purposes.

Future Outlook

The filing details future vesting schedules for the reporting person's restricted stock units, with shares from various grants vesting in successive equal quarterly installments through February 2026 and beyond, subject to continuous service.

Management Comments

• "This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."

Industry Context

This is a routine insider transaction filing (Form 4) related to executive compensation and tax obligations. It does not provide broader industry trends or competitive analysis. Such filings are common across all publicly traded companies when executives receive equity compensation that vests.

Comparison to Industry Standards

• This filing reports a standard practice for managing equity compensation. Many companies, including peers in the biotechnology and pharmaceutical sectors, utilize restricted stock units (RSUs) as part of executive compensation packages, and tax withholding upon vesting is a common mechanism.
• For example, companies like Biogen (BIIB) or Gilead Sciences (GILD) also report similar Form 4 transactions for their executives. The specific number of shares or value is relative to the individual's compensation package and the company's stock price, but the mechanism itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact. The transaction is routine and does not signal a change in management's confidence. The CFO still holds a substantial number of shares, aligning interests.
• Employees: The RSU vesting and tax withholding process is a standard component of executive compensation, reflecting the company's established equity incentive plan.

Next Steps

• Continued vesting of 10,020 shares from the February 24, 2023 RSU grant in successive equal quarterly installments through February 24, 2026.
• Continued vesting of 178,125 shares from the January 22, 2024 RSU grant in successive equal quarterly installments through January 22, 2026.
• Continued vesting of 120,000 shares from the February 25, 2025 RSU grant, with one-quarter vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary transaction for tax withholding purposes related to executive compensation. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The CFO's continued significant beneficial ownership of shares suggests ongoing alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Trading, Restricted Stock Units, Tax Withholding, Executive Compensation, Prathyusha Duraibabu